DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Disease Landscape and Forecast | G7 | 2016
Multiple label expansions of premium-priced agents and the launch of seven novel therapies will fuel the significant growth of the NHL market over the ten-year forecast period. The biosimilar…
Bladder Cancer, Malignant Melanoma, Non-Small-Cell Lung Cancer, Renal Cell Carcinoma (TBC) | Access and Reimbursement | US | 2016
Immune checkpoint inhibitors have entered multiple oncology indications but the high costs associated with these agents present significant challenges for payers. The potential for label expansions…
Chronic Obstructive Pulmonary Disease | Disease Landscape and Forecast | G7 | 2016
The large therapeutic market for chronic obstructive pulmonary disease (COPD), a disease that is closely associated with smoking, continues to expand and is expected to grow from approximately $15…